| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
DTPD-Q is an inhibitor of dynamin 1, a GTPase protein involved in clathrin-mediated endocytosis. The reported IC50 value for dynamin 1 inhibition is 273 µM.
|
|---|---|
| ln Vitro |
DTPD-Q inhibits dynamin 1 with an IC50 of 273 µM. It reduces clathrin-mediated endocytosis in serum-starved U2OS cells, with an IC50 of 120 µM. Additionally, DTPD-Q is toxic to the aquatic bacterium Vibrio fischeri, with an EC50 of 1.98 mg/L, and is less toxic to this bacterium than its parent compound DTPD.
|
| ln Vivo |
In Caenorhabditis elegans (nematode) models, exposure to DTPDQ (i.e., DTPD-Q) at concentrations of 1–10 μg/L enhances intestinal permeability. At concentrations of 1–10 μg/L, DTPDQ also induces intestinal reactive oxygen species (ROS) production and activates the oxidative stress-responsive reporters SOD-3::GFP and GST-4::GFP. In the range of 0.01–10 μg/L, DTPDQ does not induce lethality in C. elegans, nor does it affect intestinal morphology. When used at concentrations of 1 or 10 μg/ml, DTPD-Q increases intestinal permeability and ROS production in C. elegans.
|
| Enzyme Assay |
The provided documents do not contain a specific description of a non-cell-based enzyme or receptor binding assay protocol for DTPD-Q. The reported dynamin 1 inhibition data (IC50 = 273 µM) is cited from the literature but the experimental procedure is not detailed in the available search results.
|
| Cell Assay |
The provided documents do not contain a detailed description of the in vitro cell-based assay protocol for DTPD-Q. However, it has been reported that DTPD-Q reduces clathrin-mediated endocytosis in serum-starved U2OS cells, with an IC50 of 120 µM. The specific experimental conditions (e.g., cell culture methods, treatment duration, endocytosis measurement techniques) are not provided in the available search results.
|
| Animal Protocol |
In a study comparing intestinal toxicity of six PPD quinones (including DTPDQ) in Caenorhabditis elegans, the following experimental conditions were used: nematodes were exposed to DTPDQ at concentrations ranging from 0.01 to 10 μg/L. Endpoints assessed included lethality, intestinal morphology (visualized by microscopy), intestinal permeability (measured by the uptake of a fluorescent tracer), intestinal ROS production (measured by fluorescence intensity of ROS-sensitive probes), and activation of oxidative stress reporters SOD-3::GFP and GST-4::GFP. In another study, DTPD-Q was tested in C. elegans at concentrations of 1 or 10 μg/ml to assess effects on intestinal permeability and ROS production.
|
| Toxicity/Toxicokinetics |
DTPD-Q is less toxic to the aquatic bacterium Vibrio fischeri than its parent compound DTPD, with an EC50 of 1.98 mg/L. In Caenorhabditis elegans, exposure to DTPDQ at concentrations of 1–10 μg/L enhances intestinal permeability and induces intestinal ROS production; however, at concentrations up to 10 μg/L, DTPDQ does not induce lethality (at 10 μg/L, only 77PDQ caused approximately 4% lethality among the six PPDQs tested) nor does it affect intestinal morphology. At higher concentrations (1 or 10 μg/ml), DTPD-Q increases intestinal permeability and ROS production in C. elegans. DTPD-Q has been detected in environmental samples (roadway runoff water, roadside soils, indoor dust) and consumer products made from recycled tire rubber, where it accumulates and increases ecological risk.
|
| References |
| Molecular Formula |
C20H18N2O2
|
|---|---|
| Molecular Weight |
318.37
|
| Elemental Analysis |
C, 75.45; H, 5.70; N, 8.80; O, 10.05
|
| CAS # |
252950-56-4
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.302±0.06 g/cm3(Predicted)
|
| Boiling Point |
482.6±45.0 °C(Predicted)
|
| LogP |
0
|
| SMILES |
C1(=O)C=C(NC2=CC=CC=C2C)C(=O)C=C1NC1=CC=CC=C1C
|
| Synonyms |
DTPD-Q; 252950-56-4; 2,5-Bis(o-tolylamino)cyclohexa-2,5-diene-1,4-dione; CHEMBL3329970; DTXSID501352924;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~2 mg/mL (6.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1410 mL | 15.7050 mL | 31.4100 mL | |
| 5 mM | 0.6282 mL | 3.1410 mL | 6.2820 mL | |
| 10 mM | 0.3141 mL | 1.5705 mL | 3.1410 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA